索拉非尼联合卡培他滨治疗肝细胞肝癌疗效及对患者血清miR-212和miR-132水平的影响  

Curative effect of sorafenib combined with capecitabine in treatment of hepatocellular carcinoma and its influence on serum miR-212 and miR-132 levels

作　　者：曹绍华 王庆庆[1] 张金冉[1] CAO Shaohua;WANG Qingqing;ZHANG Jinran(Clinical Medicine of Affiliated Hospital of Yan'an University,Yan'an 716000)

机构地区：[1]延安大学附属医院临床药学科,延安716000

出　　处：《陕西医学杂志》2020年第5期615-618,共4页Shaanxi Medical Journal

摘　　要：目的:观察索拉非尼联合卡培他滨治疗肝细胞肝癌(HCC)的疗效及对患者血清miR-212和miR-132水平的影响。方法:选取70例HCC患者,随机数表法分为两组,试验组35例给予索拉非尼联合卡培他滨治疗,对照组35例采取索拉非尼治疗。比较两组临床疗效、血清miR-212和miR-132水平,血清白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(INF-γ)水平、不良反应发生情况及1年生存率。结果:试验组疾病控制率为82.86%高于对照组60.00%(P<0.05);治疗后,试验组的TNF-α水平低于对照组(P<0.05);治疗后,试验组的miR-212、miR-132水平均高于对照组(P<0.05);试验组患者手足综合征和恶心呕吐的发生率高于对照组(P<0.05),两组疲乏、贫血和白细胞下降的发生率相比无统计学差异(P>0.05);试验组1年生存率为74.29%(26/35)高于对照组的51.43%(18/35),差异有统计学意义(P<0.05)。结论:索拉非尼联合卡培他滨治疗HCC患者,可提高疾病控制率,患者血清miR-212和miR-132水平升高,不良反应可耐受。Objective:To observe the curative effect of sorafenib combined with capecitabine in treatment of hepatocellular carcinoma(HCC)and its influence on the levels of serum miR-212 and miR-132.Methods:A total of 70 HCC patients were enrolled and divided into two groups by random number table method,with 35 cases in each group.The experimental group was treated with sorafenib combined with capecitabine,while the control group was treated with sorafenib.The clinical curative effect,the levels of serum miR-212,miR-132,interleukin-2(IL-2),tumor necrosis factor-α(TNF-α)and interferon-γ(INF-γ),the occurrence of adverse reactions and 1-year survival rate were compared between the two groups.Results:The disease control rate of experimental group was higher than that of control group(82.86%vs.60.00%)(P<0.05).After treatment,the TNF-αlevel in the experimental group was lower than that in the control group(P<0.05),while the levels of miR-212 and miR-132 were higher than those in the control group(P<0.05).The incidence of hand-foot syndrome,and nausea and vomiting in experimental group was higher than that in the control group(P<0.05).There was no significant difference in incidence of fatigue,anemia and leukopenia between the two groups(P>0.05).The 1-year survival rate of experimental group was higher than that of control group[74.29%(26/35)vs.51.43%(18/35)](P<0.05).Conclusion:Sorafenib combined with capecitabine in treatment of HCC patients can improve disease control rate,increase the levels of serum miR-212 and miR-132.The adverse reactions can be tolerated.

关 键 词：肝细胞肝癌 治疗 卡培他滨 索拉非尼 微小RNA-212 微小RNA-132 

分 类 号：R735.7[医药卫生—肿瘤]